logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

cHL: ICER finds brentuximab vedotin regimen cost-effective vs ABVD

The BV regimen provided more QALYs in 99.9% of simulations.